CommercialCoverageMedium impact
Extracorporeal Photochemotherapy/Photopheresis 8.01.01
Excellus BlueCross BlueShield·Dermatology, Oncology, Hematology·Skin (Dermatology)
Effective date
Oct 16, 2025
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield has updated their policy for Extracorporeal Photochemotherapy/Photopheresis (ECP), effective October 16, 2025. The policy defines specific approved indications including cutaneous T-cell lymphoma, refractory graft-versus-host disease, and cardiac allograft rejection, while classifying all other uses as investigational.
Action Required
By October 16, 2025: Billing team must verify that ECP claims for Excellus members include appropriate diagnosis codes and documentation supporting approved indications (cutaneous T-cell lymphoma unresponsive to other therapy, refractory graft-versus-host disease, or recurrent cardiac allograft rejection). Claims for investigational uses including autoimmune diseases, Crohn's disease, and non-cardiac organ transplant rejection will likely be denied.